| Pharmaceutical Information |
| Drug Name |
Azelastine |
| Drug ID |
BADD_D00198 |
| Description |
Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.[L8240,L8270] Azelastine is also available in combination with fluticasone propionate as a nasal spray marketed under the trade name Dymista™, which is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older.[L8309] |
| Indications and Usage |
Intranasal azelastine is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and older.[L8240] Ophthalmic azelastine solution is indicated for the treatment of itchy eyes associated with allergic conjunctivitis.[L8270]
As a 0.15% nasal spray, azelastine hydrochloride is also indicated for over-the-counter treatment of allergies in patients aged six years and older.[L34640] |
| Marketing Status |
approved |
| ATC Code |
R01AC03; R06AX19; S01GX07 |
| DrugBank ID |
DB00972
|
| KEGG ID |
D07483
|
| MeSH ID |
C020976
|
| PubChem ID |
2267
|
| TTD Drug ID |
D00JVR
|
| NDC Product Code |
67877-477; 65162-676; 42291-094 |
| UNII |
ZQI909440X
|
| Synonyms |
azelastine | 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone | Allergodil | Astelin | azelastine hydrochloride | 4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)- phthalazinone HCl | Corifina | Loxin | Vividrin akut Azelastin | Optivar | Rhinolast | Optilast | Afluon | A 5610 | A-5610 | Azeptin |
|
| Chemical Information |
| Molecular Formula |
C22H24ClN3O |
| CAS Registry Number |
58581-89-8 |
| SMILES |
CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
